Bota Bio and Medichem Announce Commercial Collaboration to Advance Sustainable API Manufacturing

August 25, 2022Bota Bio——A global industrial biotechnology company dedicated to advancing sustainable bio-manufacturing,Medichem——A comprehensive pharmaceutical company focused on the process development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs),Officially Announces the Launch of Commercial Development Partnership, aiming to reduce API manufacturing costs while empowering sustainable development.

Bota BioandMedichemThey will jointly advance two high-value API projects. Bota will be responsible for developing novel enzymes to enable efficient catalysis and sustainable production, thereby minimizing the need for expensive reagents and intermediates during the manufacturing process. Medichem will handle API R&D, scale-up, manufacturing, and commercial operations at its facilities in Spain and Malta.

“We are delighted to partner with Medichem, which brings over 50 years of experience in the development, manufacturing, and commercialization of APIs and FDFs.”Dr. Cheryl Cui, Co-founder and CEO of Bota Biosciences“He stated that ‘Bota will leverage its technological platform advantages to unlock the potential of biology, delivering innovative solutions to our customers and making the sustainable production of industrial products, such as active pharmaceutical ingredients (APIs), a reality. This collaboration demonstrates the commitment of both Bota and Medichem to environmental sustainability.’”

“The pharmaceutical industry urgently needs sustainable methods for producing key active ingredients. Enzymes offer an excellent solution. However, unengineered enzymes have failed to gain widespread adoption due to their low activity and poor stability. We are delighted to embark on an innovative collaboration with Bota Biosciences, as Bota has assembled an industry-leading enzyme engineering team and achieved revolutionary breakthroughs in pharmaceutical manufacturing and processes.”Medichem's Chief Operating Officer, Jose Luis Rodriguez Mirandastated, “We believe that the novel biocatalytic processes developed based on Bota will not only optimize production processes but also play a significant role in achieving our environmental sustainability goals.”

Bota BioBota Biosciences is a biotechnology company founded on the principles of synthetic biology. By building a standardized, automated, high-throughput experimental platform and integrating machine learning and artificial intelligence, the company systematically engineers organisms to develop efficient, green, low-cost industrial biotechnologies suitable for large-scale production. It provides key technological solutions for various industries, including chemicals, food, agriculture, and pharmaceuticals. The company’s core technology and management teams hail from top global universities such as MIT and Harvard, as well as pioneering synthetic biology companies like Amyris, Ginkgo Bioworks, Zymergen, and Codexis. Bota was successfully selected for MIT Technology Review’s “50 Smart Companies” list in 2020 and was included in the American Chemical Society’s C&EN “10 Startups to Watch in 2021.”

Medichem S.A.It is a family-owned business headquartered in Barcelona, Spain, with R&D centers and manufacturing bases located in Spain and Malta. This family-owned enterprise (Medichem S.A. and the former Combino Pharm S.L.) has been dedicated to the production of pharmaceutical products since the 1970s. Currently, it offers more than 45 APIs and 20 FDFs for sale. Medichem aims to make a positive impact on society and the planet, having embarked on its sustainability journey long ago, and is currently advancing its 2022–2026 strategic sustainability plan through cross-sector collaboration. For more information, please visit the official website at www.medichem.es, or follow the LinkedIn company pages: Medichem S.A. and Medichem Manufacturing Malta.